QCLS Q/C TECHNOLOGIES, INC.

NEUTRAL Impact: 2/10 10-K/A
Horizon days Filed Apr 29, 2026 Processed 1mo ago SEC 0001493152-26-019663
Amended annual report (potential restatement)
Latest settled — T+20d
QCLS ▲ +16.53% at T+20d
NEUTRAL call ✓ call won +16.53% · α vs SPY +11.31% · entry $3.75 → $4.37
Next anchor: T+60d in 6w
Currently $3.79 · +1.07% from $3.75 entry
Entry anchored
Apr 29, 2026
via day open
T+1d
-0.53%
call -0.53% · α -0.75%
$3.73
settled 6w ago
T+5d
+0.27%
call +0.27% · α -1.46%
$3.76
settled 5w ago
T+20d
+16.53%
call +16.53% · α +11.31%
$4.37
settled 13d ago
T+60d
—
call — · α —
—
in 6w

Price Chart

Loading chart...

Executive Summary

Q/C Technologies filed Amendment No. 1 to its 2025 10-K solely to add Part III items (director/executive compensation, beneficial ownership, related transactions, and auditor fees) that were omitted from the original filing. The amendment does not change any financial statements or previously reported results. The filing follows a recent auditor change (March 2026) and a late 10-Q filing notice (November 2025), but this amendment is purely administrative.

Actionable Insight

The filing is routine and does not affect the stock's fundamental outlook. However, the combination of a late 10-Q, auditor change, and delayed proxy filing suggests potential control weaknesses. Monitor for the eventual definitive proxy statement and any subsequent restatements or SEC inquiries.

Key Facts

  • Amendment adds only Part III items (10, 11, 12, 13, 14) omitted from original 10-K filed March 15, 2026.
  • No changes to financial statements, business operations, or risk factors.
  • Auditor changed from Stephano Slack to Grassi & Co. on March 9, 2026, disclosed in prior 8-K.
  • Late NT 10-Q filed November 14, 2025 for Q3 2025; no restatement noted in this amendment.
  • PharmaCyte Biotech Inc. owns 44.90% of common stock as of April 26, 2026.
  • Executive Chairman Joshua Silverman entered a new 3-year employment agreement on April 13, 2026.

Financial Impact

No financial impact from this administrative amendment.

Risk Factors

  • Potential ongoing internal control or financial reporting issues given the late filing and auditor change.
  • Concentrated ownership by PharmaCyte (44.9%) could lead to governance or control events.

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
10-K/A Filing (Primary)0001493152-26-019663
Exhibit: ex32-1.htm0001493152-26-019663
Exhibit: ex32-2.htm0001493152-26-019663
Document: 0001493152-26-019663-index-headers.html0001493152-26-019663
Document: 0001493152-26-019663-index.html0001493152-26-019663
Document: 0001493152-26-019663.txt0001493152-26-019663

US Market Status

Market Closed — Opens Thu (11h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access